Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 50: 1445-1447, 2004. First published May 27, 2004; 10.1373/clinchem.2004.035493
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2004.035493v1
50/8/1445    most recent
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dorssers, L. C.J.
Right arrow Articles by Sweep, C.G.J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dorssers, L. C.J.
Right arrow Articles by Sweep, C.G.J.
Related Collections
Right arrow Cancer Diagnostics (since 2002)
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2004;50:1445-1447.)
© 2004 American Association for Clinical Chemistry, Inc.

Technical Briefs

Application of a Newly Developed ELISA for BCAR1 Protein for Prediction of Clinical Benefit of Tamoxifen Therapy in Patients with Advanced Breast Cancer

Lambert C.J. Dorssers1, Nicolai Grebenchtchikov3, Arend Brinkman1, Maxime P. Look2, Jan G.M. Klijn2, Anneke Geurts-Moespot3, Paul N. Span3, John A. Foekens2 and C.G.J. (Fred) Sweep3,a

1 Department of Pathology, Division of Molecular Biology, and2 Department of Medical Oncology, Erasmus MC Rotterdam, Rotterdam, The Netherlands;3 Department of Chemical Endocrinology, University Medical Centre Nijmegen, Nijmegen, The Netherlands

aaddress correspondence to this author at: Department of Chemical Endocrinology, University Medical Centre Nijmegen, PO Box 9101, 6500 HB Nijmegen, The Netherlands; fax 31-243541484, e-mail F.Sweep@ace.umcn.nl

The first 20% of the full text of this article appears below.

Advanced breast cancer is frequently treated with the antiestrogen tamoxifen. Response is observed in approximately one half of estrogen receptor (ER)-positive patients but ultimately fails because the cancer becomes resistant. The mechanisms for resistance of breast cancer to tamoxifen treatment are not yet understood (1). The breast cancer anti-estrogen resistance protein 1 (BCAR1) gene was identified in a search for genes that cause proliferation of estrogen-dependent breast cancer cells in the presence of an antiestrogen drug (2). To assess the role of the BCAR1 protein in breast cancer progression, we developed a specific and sensitive ELISA. Here we report the use of this BCAR1 ELISA to measure BCAR1 protein concentrations in human breast cancer cytosols to predict success of tamoxifen treatment for advanced disease.

Primary invasive breast tumors were collected between 1978 and June 1995. Our study design was approved by the medical ethics committee of the Erasmus MC Rotterdam. Selection of samples for analysis of response to tamoxifen in recurrent breast cancer was based on the availability of stored cytosol extracts (in liquid nitrogen), which remained after routine ER and progesterone receptor analyses (3). Tissue specimens that were sampled after neoadjuvant treatment or obtained from a biopsy were not included. In addition, the samples selected were only from ER-positive (>10 fmol/mg of protein) tumors of patients who developed recurrent disease and were treated with tamoxifen as first-line therapy. Of these 592 patients, 133 had received adjuvant chemotherapy (89 receiving cyclophosphamide–methotrexate–5-fluorouracil and 44 receiving 5-fluorouracil–epirubicin–cyclophosphamide), and none had received adjuvant hormonal therapy. The median age at the start of tamoxifen treatment for recurrent disease was 61 years (range, 28–91 years); 144 patients were premenopausal and 448 were postmenopausal. During the follow-up period, . . . [Full Text of this Article]




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Cancer Res.Home page
L. C. J. Dorssers, N. Grebenchtchikov, A. Brinkman, M. P. Look, S. P. J. van Broekhoven, D. de Jong, H. A. Peters, H. Portengen, M. E. Meijer-van Gelder, J. G. M. Klijn, et al.
The Prognostic Value of BCAR1 in Patients with Primary Breast Cancer
Clin. Cancer Res., September 15, 2004; 10(18): 6194 - 6202.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Association for Clinical Chemistry.